NASDAQ:SGYP Synergy Pharmaceuticals Stock Forecast, Price & News Notice: This company has been marked as potentially delisted and may not be actively trading. Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Synergy Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add Add Compare Share Today's Range N/A50-Day Range$0.01MA: $0.02▼$0.0352-Week Range N/AVolumeN/AAverage Volume6.08 million shsMarket Capitalization$7.44 millionP/E RatioN/ADividend YieldN/ABeta4.94 ProfileAnalyst RatingsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Synergy Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat gastrointestinal diseases and disorders. Its lead product is plecanatide, a novel uroguanylin based gastrointestinal platform that is traded under the TRULANCE name for the treatment of chronic idiopathic constipation and irritable bowel syndrome. The company also develops dolcanatide to treat mild-to-moderate ulcerative colitis. It has a licensing agreement with Cipher Pharmaceuticals Inc. to develop, market, distribute, and sell TRULANCE in Canada. Synergy Pharmaceuticals Inc. is headquartered in New York, New York. On December 12, 2018, Synergy Pharmaceuticals Inc. along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of New York.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Synergy Pharmaceuticals. Previous Next 3.0 Community Rank Outperform VotesSynergy Pharmaceuticals has received 754 “outperform” votes. (Add your “outperform” vote.)Underperform VotesSynergy Pharmaceuticals has received 513 “underperform” votes. (Add your “underperform” vote.)Community SentimentSynergy Pharmaceuticals has received 59.51% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Synergy Pharmaceuticals and other stocks. Vote “Outperform” if you believe SGYP will outperform the S&P 500 over the long term. Vote “Underperform” if you believe SGYP will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldSynergy Pharmaceuticals does not currently pay a dividend.Dividend GrowthSynergy Pharmaceuticals does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Synergy Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.80% of the stock of Synergy Pharmaceuticals is held by insiders.Percentage Held by InstitutionsOnly 28.47% of the stock of Synergy Pharmaceuticals is held by institutions. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Synergy Pharmaceuticals is -0.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Synergy Pharmaceuticals is -0.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next Analyst Opinion: 0.0Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.60 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:SGYP Previous Symbol CUSIP87163930 CIK1347613 Webwww.synergypharma.com Phone212-297-0020Debt Debt-to-Equity RatioN/A Current Ratio0.52 Quick Ratio0.38Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$16.82 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value($0.02) per share Price / BookN/AProfitability EPS (Most Recent Fiscal Year)($1.02) Net Income$-224,330,000.00 Net Margins-332.11% Return on EquityN/A Return on Assets-118.14%Miscellaneous EmployeesN/A Outstanding Shares248,040,000Market Cap$7.44 million Next Earnings DateN/A OptionableOptionable Receive SGYP News and Ratings via Email Sign-up to receive the latest news and ratings for SGYP and its competitors with MarketBeat's FREE daily newsletter. Synergy Pharmaceuticals (NASDAQ:SGYP) Frequently Asked Questions How were Synergy Pharmaceuticals' earnings last quarter? Synergy Pharmaceuticals Inc (NASDAQ:SGYP) announced its quarterly earnings data on Thursday, November, 8th. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.13) by $0.01. The biopharmaceutical company earned $11.11 million during the quarter, compared to analyst estimates of $15.65 million. View Synergy Pharmaceuticals' earnings history. Who are some of Synergy Pharmaceuticals' key competitors? Some companies that are related to Synergy Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), Immunomedics (IMMU), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), BioMarin Pharmaceutical (BMRN), Neurocrine Biosciences (NBIX) and Repligen (RGEN). View all competitors. What other stocks do shareholders of Synergy Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Synergy Pharmaceuticals investors own include Novavax (NVAX), Immunomedics (IMMU), Progenics Pharmaceuticals (PGNX), Inovio Pharmaceuticals (INO), ACADIA Pharmaceuticals (ACAD), Cara Therapeutics (CARA), Opko Health (OPK), Gilead Sciences (GILD), Exelixis (EXEL) and SLS International (SLS). Who are Synergy Pharmaceuticals' key executives? Synergy Pharmaceuticals' management team includes the following people: Mr. Troy Hamilton Pharm.D., CEO & Director (Age 47)Mr. Gary G. Gemignani, Exec. VP & CFO (Age 54)Gem Gokmen Hopkins, VP of Investor Relations and Corp. CommunicationsMs. Pamela Cebulski, Sr. VP of MarketingMs. Marianne Jackson, Sr. VP of Sales & Market Access What is Synergy Pharmaceuticals' stock symbol? Synergy Pharmaceuticals trades on the NASDAQ under the ticker symbol "SGYP." How big of a company is Synergy Pharmaceuticals? Synergy Pharmaceuticals has a market capitalization of $0.00 and generates $16.82 million in revenue each year. The biopharmaceutical company earns $-224,330,000.00 in net income (profit) each year or ($1.02) on an earnings per share basis. What is Synergy Pharmaceuticals' official website? The official website for Synergy Pharmaceuticals is www.synergypharma.com. How can I contact Synergy Pharmaceuticals? Synergy Pharmaceuticals' mailing address is 420 LEXINGTON AVENUE SUITE 2012, NEW YORK NY, 10170. The biopharmaceutical company can be reached via phone at 212-297-0020 or via email at [email protected] This page was last updated on 10/1/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
